Latest News of ABBV
AbbVie Seeks Accelerated FDA OK of Teliso-V in Non-Small Cell Lung Cancer
By MarketWatch |
3 days ago
AbbVie seeks accelerated FDA approval for teliso-V, an antibody-drug conjugate for c-Met overexpressing non-small cell lung cancer. This treatment targets a specific group of patients with a poor prog...
AbbVie's Parkinson's disease drug meets main goal in late-stage trial
By Yahoo! Finance |
4 days ago
AbbVie's drug, tavapadon, successfully met the main goal in a late-stage trial for early Parkinson's disease. Patients showed improvement compared to placebo, as evaluated on a disease rating scale....
Bausch Reportedly Eyes A Sale; Could J&J Or AbbVie Buy It?
By Investor's Business Daily |
2 weeks ago
Bausch + Lomb stock surged amid reports of a potential sale, with private equity seen as the likely buyer due to antitrust challenges for other companies. The parent company, Bausch Health, faces pate...
-
Can AbbVie Regain Its Status As a Top Dividend Growth Stock?
By Yahoo! Finance | 2 weeks agoAbbVie, known for its strong dividend growth, faces challenges post-Humira patent expiration. Despite slower dividend growth, its pipeline and acquisitions offer hope for recovery. Investors should mo...
-
Pfizer Stock Vs. AbbVie
By Forbes | 2 weeks agoPfizer stock (NYSE: PFE) is favored over AbbVie due to its better valuation. With a lower multiple and strong revenue growth potential, Pfizer is expected to outperform AbbVie in the coming years....
-
Daily Dividend Report: Salesforce, Brady, META, Abbvie, UTZ Brands
By Forbes | 3 weeks agoSalesforce, Brady, Meta Platforms, AbbVie, and Utz Brands have all declared quarterly dividends for their shareholders, ranging from $0.24 to $1.55 per share, payable in October and November 2024....
-
Is AbbVie Inc. (ABBV) the Best Cancer Stock to Buy Now?
By Yahoo! Finance | 3 weeks agoThe global oncology market is rapidly growing, with an expected value of over $470 billion by 2032. AbbVie Inc. is a leading player, making strides in cancer treatment development and acquisitions. De...
-
AbbVie Inc (ABBV): A Good 52-Week High Stock to Buy According to Short Sellers
By Yahoo! Finance | 4 weeks agoInsider Monkey compiled a list of the 14 Best 52-Week High Stocks to Buy, including AbbVie Inc (NYSE:ABBV). The stock market is thriving, driven by gains in various sectors....
-
We Think You Can Look Beyond AbbVie's (NYSE:ABBV) Lackluster Earnings
By Yahoo! Finance | 1 month agoAbbVie Inc.'s stock market performance remained stable despite weak earnings, which may be stronger than perceived. The company's accrual ratio of -0.19 indicates higher free cash flow than profit, af...
-
Decoding AbbVie Inc (ABBV): A Strategic SWOT Insight
By Yahoo! Finance | 1 month agoAbbVie Inc, a leading biopharmaceutical company, reported strong financials in its recent 10-Q filing, with a diverse product portfolio and focus on innovation. Strategic acquisitions and pipeline exp...
-
Insider Sale: Executive Chairman Richard Gonzalez Sells 66,500 Shares of AbbVie Inc (ABBV)
By Yahoo! Finance | 1 month agoAbbVie Inc is a biopharmaceutical company focused on innovative therapies. The recent insider sell-off by Richard Gonzalez, totaling 487,961 shares, raises concerns as the stock is deemed significantl...
-
Stocks Showing Improving Market Leadership: AbbVie Earns 86 RS Rating
By Investor's Business Daily | 1 month agoLearn how to scale out of losing stocks using three signals, including IBD's RS Rating that tracks a stock's technical performance over 52 weeks compared to others. Explore AbbVie's extended status an...
-
AbbVie's Q2 2024 net earnings drop to $1.37bn
By Yahoo! Finance | 2 months agoAbbVie's Q2 2024 financial results show a 32.1% decrease in net earnings to $1.37bn, with diluted EPS down by 32.5%. Despite this, global net revenues increased by 4....
-
AbbVie (ABBV) Q2 2024 Earnings Call Transcript
By Yahoo! Finance | 2 months agoAbbVie remains confident in its aesthetics business despite economic headwinds, with strong growth expected in the long term. The company is well-positioned to navigate potential policy changes under ...
-
AbbVie's Q2 Earnings Beat Estimates, Raises Annual Profit On Strong Sales From Newer Immunology And Cancer Drugs
By Yahoo! Finance | 2 months agoAbbVie reported net revenues of $14.46 billion, surpassing expectations. Sales increased across immunology, oncology, and neuroscience products. The company raised its 2024 adjusted EPS guidance. AbbV...